REFERENCE CODE GDME1034FPR PUBLICATION DATE DECEMBER 2014 NUCLEAR IMAGING - CURRENT AND FUTURE PLAYERS

Transcription

1 REFERENCE CODE GDME1034FPR PUBLICATION DATE DECEMBER 2014 NUCLEAR IMAGING -

2 List of Tables List of Figures Introduction Catalyst Related Reports Competitive Assessment Overview Dedicated PET Systems Overview Product Profile SWOT Analysis PET/CT Systems Overview Product Profiles SWOT Analysis PET/MRI Systems Overview Product Profile SWOT Analysis Dedicated SPECT Systems

3 3.5.1 Overview Product Profile SWOT Analysis SPECT/CT Systems Overview Product Profile SWOT Analysis PET/Ultrasound and SPECT/Ultrasound Systems Overview Product Profile SWOT Analysis Pipeline Assessment Overview Pipeline by Phases in Development Product Profiles Brain Biosciences CerePET ECORAD Dual Modality Imager FMI Technologies ScintiStar PET/CT IntraMedical Imaging Marginator Beta Camera INSERT SPECT/MRI Nucare/Zecotek Photonics New Generation PET Scanning Device Philips Healthcare PET Alpha Ring Detector Photo Diagnostic Systems NeuroPET/CT

4 4.3.9 SynchroPET Breast PET/MRI SynchroPET Wrist Scanner SurgicEye SPECT Hybrid Clinical Trials to Watch Overview Clinical Trial Profiles Current and Future Players Overview Trends in Corporate Strategy Company Profiles DDD-Diagnostic Digirad GE Healthcare GVI Medical Devices Mediso Medical Imaging Systems NeuroLogica Neusoft Medical Systems NuCare Medical Systems Oncovision Philips Healthcare Shimadzu Siemens Healthcare SurgicEye

5 Toshiba Medical Other Companies Appendix Abbreviations Bibliography Methodology Overview Coverage Secondary Research Physicians and Specialists Included in This Study Primary Research Primary Research Key Opinion Leader Interviews Expert Panel Validation Stakeholder Survey Forecasting Methodology About the Authors Andrew Thompson, PhD, Senior Analyst Priya Radhakrishnan, MBA, Director, Medical Devices Bonnie Bain, PhD, Global Head of Healthcare About GlobalData Disclaimer

6 1.1 List of Tables Table 1: Dedicated PET Scanners Table 2: Dedicated PET SWOT Analysis Table 3: PET/CT Scanners Table 4: PET/CT SWOT Analysis Table 5: PET/MRI Systems Table 6: PET/MRI SWOT Analysis Table 7: Dedicated SPECT Systems Table 8: Dedicated SPECT SWOT Analysis Table 9: SPECT/CT Systems Table 10: SPECT/CT SWOT Analysis Table 11: SPECT-Ultrasound Systems Table 12: SPECT/Ultrasound SWOT Analysis Table 13: Nuclear Imaging Pipeline, Table 14: CerePET SWOT Analysis Table 15: ECORAD Dual Modality Imager SWOT Analysis Table 16: ScintiStar PET/CT SWOT Analysis Table 17: Marginator SWOT Analysis Table 18: INSERT SPECT-MRI SWOT Analysis Table 19: Nucare/Zecotek Photonics New Generation PET Scanning Device SWOT Analysis Table 20: PET Alpha Ring Detector Table 21: NeuroPET/CT Scanner SWOT Analysis Table 22: SynchroPET Breast PET/MRI SWOT Analysis Table 23: SynchroPET Wrist Scanner

7 Table 24: SurgicEye SPECT/Ultrasound device SWOT Analysis Table 25: Key Clinical Trials Table 26: Company Profile DDD-Diagnostic Table 27: DDD-Diagnostic SWOT Analysis Table 28: Company Profile Digirad Table 29: Digirad SWOT Analysis Table 30: Company Profile GE Healthcare Table 31: GE Healthcare Product Portfolio Table 32: GE Healthcare SWOT Analysis Table 33: Company Profile GVI Medical Devices Table 34: GVI Medical Devices SWOT Analysis Table 35: Company Profile Mediso Medical Imaging Systems Table 36: Mediso Medical Imaging Systems SWOT Analysis Table 37: Company Profile Neurologica Table 38: Neurologica SWOT Analysis Table 39: Company Profile Neusoft Medical Systems Table 40: Neusoft Medical Systems SWOT Analysis Table 41: Company Profile NuCare Medical Systems Table 42: Nucare Medical Systems SWOT Analysis Table 43: Company Profile Oncovision Table 44: Oncovision SWOT Analysis Table 45: Company Profile Philips Healthcare Table 46: Philips Healthcare SWOT Analysis Table 47: Company Profile Shimadzu

8 Table 48: Shimadzu SWOT Analysis Table 49: Company Profile Siemens Healthcare Table 50: Siemens Healthcare SWOT Analysis Table 51: Company Profile SurgicEye Table 52: SurgicEye SWOT Analysis Table 53: Company Profile Toshiba Medical Table 54: Toshiba Medical SWOT Analysis Table 55: Other Companies in the Nuclear Imaging Market, Table 56: Primary Research Summary Table 57: Primary Research Participants Affiliation List of Figures Figure 1: Primary Research Summary Figure 2: Primary Research Participants Affiliation

9 Introduction 2 Introduction An early diagnosis of disease is the foundation of increasing survival rates. Single-photon emission computed tomography (SPECT) and positron emission tomography (PET) imaging are diagnostic imaging techniques that are widely used in a variety of disease areas including oncology, cardiovascular disease, bone disease, and infectious disease. This report provides an analysis of the nuclear imaging market, with a particular focus on SPECT and PET imaging and hybrid modalities. 2.1 Catalyst PET and SPECT imaging are well-established techniques in the nuclear imaging market. The advent of hybrid imaging has enabled PET/CT imaging to undergo explosive growth, but this has increased demand on struggling healthcare budgets. New developments in hybrid nuclear imaging promise to further increase the utility of these technologies, while significantly improving patient cost savings and safety by reducing the repeated or examinations. However, these improvements come with a significant increase in the capital cost of equipment. This report examines how new technologies can emerge in the face of healthcare reform and other economic pressures that may affect the demand for nuclear imaging. Further, it focuses on the industry trends, promising pipeline products, and competitive landscape of nuclear imaging. 2.2 Related Reports GlobalData (2013). MediFocus: Future of Molecular Imaging, August, 2013, GDME002MFR. GlobalData (2013). MediPoint: Breast Cancer Imaging Global Analysis and Market Forecasts, May, 2013, GDME0166MAR. GlobalData (2014). MediPoint: Diagnostic Ultrasound Imaging - Global Analysis and Market Forecasts, January 2014, GDME0182MAR. GlobalData (2014). MediPoint: Diagnostic X-ray Imaging - Global Analysis and Market Forecasts, July 2014, GDME0203MAR. 9

10 Appendix 7.8 About GlobalData GlobalData is a leading global provider of business intelligence in the Healthcare industry. GlobalData provides its clients with up-to-date information and analysis on the latest developments in drug research, disease analysis, and clinical research and development. Our integrated business intelligence solutions include a range of interactive online databases, analytical tools, reports and forecasts. Our analysis is supported by a 24/7 client support and analyst team. GlobalData has offices in New York, San Francisco, Boston, London, India, Korea, Japan, Singapore, and Australia. 7.9 Disclaimer All Rights Reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form by any means, electronic, mechanical, photocopying, recording, or otherwise, without the prior permission of the publisher, GlobalData. 133